ONCR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ONCR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-Revenue measures a company's ability to pay off its debt.
Oncorus's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $21.73 Mil. Oncorus's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $47.52 Mil. Oncorus's annualized Revenue for the quarter that ended in Mar. 2023 was $0.00 Mil.
The historical data trend for Oncorus's Debt-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncorus Annual Data | |||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | ||||||
Debt-to-Revenue | N/A | N/A | N/A | N/A | N/A |
Oncorus Quarterly Data | |||||||||||||||||
Dec18 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | |
Debt-to-Revenue | Get a 7-Day Free Trial | N/A | N/A | N/A | N/A | N/A |
For the Biotechnology subindustry, Oncorus's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Oncorus's Debt-to-Revenue distribution charts can be found below:
* The bar in red indicates where Oncorus's Debt-to-Revenue falls into.
Debt-to-Revenue measures a company's ability to pay off its debt.
Oncorus's Debt-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as
Debt-to-Revenue | = | Total Debt | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (20.565 | + | 47.854) | / | N/A | |
= | N/A |
Oncorus's annualized Debt-to-Revenue for the quarter that ended in Mar. 2023 is calculated as
Debt-to-Revenue | = | Total Debt | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (21.725 | + | 47.524) | / | 0 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2023) Revenue data.
Thank you for viewing the detailed overview of Oncorus's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Brian J. Shea | officer: Interim CEO | C/O ONCORUS, INC., 4 CORPORATE DRIVE, ANDOVER MA 01810 |
Alexander Nolte | officer: Interim CFO | 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451 |
James E Flynn | director, 10 percent owner, other: *Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Douglas Fambrough | director | C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON MA 02421 |
Rick Wanstall | officer: CFO and Treasurer | C/O AILERON THERAPEUTICS, INC., 490 ARSENAL WAY, WATERTOWN MA 02472 |
Stephen Harbin | officer: COO and Chief of Staff | C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139 |
Barbara Yanni | director | 1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406 |
Eric Rubin | director | C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139 |
Christophe Queva | officer: CSO and SVP, Research | C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139 |
Scott A Canute | director | FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803 |
Mpm Bioventures 2014, L.p. | 10 percent owner | C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142 |
Luke Evnin | director, 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116 |
Oncology Impact Fund (cayman) Management L.p. | 10 percent owner | 450 KENDALL STREET, CAMBRIDGE MA 02142 |
Mpm Asset Management Investors Sunstates Fund Llc | 10 percent owner | 450 KENDALL STREET, CAMBRIDGE MA 02142 |
Ansbert Gadicke | 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-16-2022
By GuruFocusNews GuruFocusNews • 06-19-2022
By Value_Insider Value_Insider • 11-18-2022
By sperokesalga sperokesalga • 03-24-2023
By GuruFocusNews GuruFocusNews • 06-09-2022
By GuruFocusNews GuruFocusNews • 07-09-2022
By PurpleRose PurpleRose • 07-13-2022
By Stock market mentor Stock market mentor • 01-04-2023
By GuruFocusNews GuruFocusNews • 07-06-2022
By GuruFocusNews GuruFocusNews • 06-11-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.